Part 1: How one digital therapy got an NDC, and why it will be the last.

Issue 054.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I shared new financial details surrounding three recent M&A deals. Next week I'll write Part II of how a piece of software gets coded like a drug. Here's what's happening this week:

After a presentation on digital health business models to 100+ health startups in Finland, Sweden, and Iceland, I spent the rest of this week trying to wrap my head around NDC vs UDI coding. Read Part I: How Welldoc got an NDC code -- after the jump.
One of the newer prescription digital therapeutics companies I've been tracking (Issue 035) is IBS-focused Mahana Therapeutics. A new Medium post from the company reveals that Mahana's first product will be named Parallel: "Together, we’ve made major strides in a short amount of time. This includes the development of Parallel, Mahana’s first product,

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Part 1: How one digital therapy got an NDC, and why it will be the last.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.